TY - JOUR
T1 - Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
AU - Steinberg, Benjamin A.
AU - Peterson, Eric D.
AU - Kim, Sunghee
AU - Thomas, Laine
AU - Gersh, Bernard J.
AU - Fonarow, Gregg C.
AU - Kowey, Peter R.
AU - Mahaffey, Kenneth W.
AU - Sherwood, Matthew W.
AU - Chang, Paul
AU - Piccini, Jonathan P.
AU - Ansell, Jack
N1 - Publisher Copyright:
© 2014 The Authors.
PY - 2015/2/3
Y1 - 2015/2/3
N2 - Background: Temporary interruption of oral anticoagulation for procedures is often required, and some propose using bridging anticoagulation. However, the use and outcomes of bridging during oral anticoagulation interruptions in clinical practice are unknown. Methods and Results: The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry is a prospective, observational registry study of US outpatients with atrial fibrillation. We recorded incident temporary interruptions of oral anticoagulation for a procedure, including the use and type of bridging therapy. Outcomes included multivariableadjusted rates of myocardial infarction, stroke or systemic embolism, major bleeding, cause-specific hospitalization, and death within 30 days. Of 7372 patients treated with oral anticoagulation, 2803 overall interruption events occurred in 2200 patients (30%) at a median follow-up of 2 years. Bridging anticoagulants were used in 24% (n=665), predominantly low-molecularweight heparin (73%, n=487) and unfractionated heparin (15%, n=97). Bridged patients were more likely to have had prior cerebrovascular events (22% versus 15%; P=0.0003) and mechanical valve replacements (9.6% versus 2.4%; P<0.0001); however, there was no difference in CHA2DS2-VASc scores (scores ≥2 in 94% versus 95%; P=0.5). Bleeding events were more common in bridged than nonbridged patients (5.0% versus 1.3%; adjusted odds ratio, 3.84; P<0.0001). The incidence of myocardial infarction, stroke or systemic embolism, major bleeding, hospitalization, or death within 30 days was also significantly higher in patients receiving bridging (13% versus 6.3%; adjusted odds ratio, 1.94; P=0.0001). Conclusions: Bridging anticoagulation is used in one quarter of anticoagulation interruptions and is associated with higher risk for bleeding and adverse events. These data do not support the use of routine bridging, and additional data are needed to identify best practices concerning anticoagulation interruptions. Clinical Trial Registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01165710.
AB - Background: Temporary interruption of oral anticoagulation for procedures is often required, and some propose using bridging anticoagulation. However, the use and outcomes of bridging during oral anticoagulation interruptions in clinical practice are unknown. Methods and Results: The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry is a prospective, observational registry study of US outpatients with atrial fibrillation. We recorded incident temporary interruptions of oral anticoagulation for a procedure, including the use and type of bridging therapy. Outcomes included multivariableadjusted rates of myocardial infarction, stroke or systemic embolism, major bleeding, cause-specific hospitalization, and death within 30 days. Of 7372 patients treated with oral anticoagulation, 2803 overall interruption events occurred in 2200 patients (30%) at a median follow-up of 2 years. Bridging anticoagulants were used in 24% (n=665), predominantly low-molecularweight heparin (73%, n=487) and unfractionated heparin (15%, n=97). Bridged patients were more likely to have had prior cerebrovascular events (22% versus 15%; P=0.0003) and mechanical valve replacements (9.6% versus 2.4%; P<0.0001); however, there was no difference in CHA2DS2-VASc scores (scores ≥2 in 94% versus 95%; P=0.5). Bleeding events were more common in bridged than nonbridged patients (5.0% versus 1.3%; adjusted odds ratio, 3.84; P<0.0001). The incidence of myocardial infarction, stroke or systemic embolism, major bleeding, hospitalization, or death within 30 days was also significantly higher in patients receiving bridging (13% versus 6.3%; adjusted odds ratio, 1.94; P=0.0001). Conclusions: Bridging anticoagulation is used in one quarter of anticoagulation interruptions and is associated with higher risk for bleeding and adverse events. These data do not support the use of routine bridging, and additional data are needed to identify best practices concerning anticoagulation interruptions. Clinical Trial Registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01165710.
KW - Anticoagulants
KW - Atrial Fibrillation
KW - Outcome assessment (health care)
UR - http://www.scopus.com/inward/record.url?scp=84923684108&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84923684108&partnerID=8YFLogxK
U2 - 10.1161/CIRCULATIONAHA.114.011777
DO - 10.1161/CIRCULATIONAHA.114.011777
M3 - Article
C2 - 25499873
AN - SCOPUS:84923684108
SN - 0009-7322
VL - 131
SP - 488
EP - 494
JO - Circulation
JF - Circulation
IS - 5
ER -